Abstract
dc:description.abstractFriedreich's Ataxia (FRDA) is a disorder that decreases levels of the mitochondrial protein Frataxin. Frataxin deficiency disrupts mitochondrial electron transport chain and iron homeostasis, leading to electron leakage, superoxide production, and reduced ATP. DNA damage and production of reactive oxygen species may cause senescence, a physiologic mechanism whereby a proliferating cell undergoes cell cycle arrest and can undergo a secretory inflammatory phenotype. Here, we tested a new FRDA therapy using nanoparticles with versatile enzymatic properties we term, "Pleozymes." Pleozymes are synthesized from the oxidation of activated charcoal (OAC), generating 3 nM discs, which act as pleiotropic redox mediators for mitochondrial electron transport and act as superoxide dismutase mimetics. OACs permit covalent bonding of molecules, such as Polyethylene-glycol, for enhanced biodistribution (PEG-OAC Pleozymes) and therapeutics, here we add the iron chelator deferoxamine (DEF-OAC-PEG Pleozymes). We hypothesize that pleozymes, especially DEF-OAC-PEGs, because of both mitochondrial dysfunction and iron dyshomeostasis, will reduce senescence in FRDA cells. AHI and FRDA cell lines increase senescence without pleozyme treatment with different patterns. Without pleozymes, senescence increased in FRDA cell lines following two patterns: increased levels after the first passage or plateauing after the second passage. Without pleozymes, senescence increased in AHI cell lines but not as prominently until the fourth passage. With pleozymes, senescence decreased in all FRDA cell lines by passage 2 or 3, DEF-OAC-PEG showing a greater decrease than the PEG-OAC in 4 out of 5 cell lines (p < 0.01-0.05 vs. untreated), and equal in the fifth cell line (p < 0.01 vs. untreated). In cells from matched AHI cell lines, OAC treatment reduced senescence but only by passage 4, with the DEF and non-DEF OAC equal or favoring PEG-OAC (p < 0.01 vs. untreated). Results suggest pleozymes decrease senescence in FRDA cell lines compared to AHIs, likely due to mitochondrial oxidative injuries in FRDAs. DEF-OAC-PEGs were generally superior to PEG-OACs in FRDA cell lines, as hypothesized, while PEG-OACs were favored in AHIs. DEFOAC-PEG's therapeutic potential may be explained by deferoxamine's iron chelation, which aids in FRDA's iron dyshomeostasis, given their Frataxin deficiency. This study provides a new therapeutic pathway for Friedreich's Ataxia.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- Masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Department thesis:degree_department
- School of Medicine
- Grantor
- Texas A&M University
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Perli, Elias
- Advisor dc:contributor.advisor
-
- Huston, David
- Committee member dc:contributor.committeemember
-
- Hegde, Muralidhar
- ORCID person:identifier.orcid
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- English
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/1969.1/1595467